Article
Multicenter Phase II Study of Panitumumab in Platinum Pretreated, Advanced Head and Neck Squamous Cell Cancer.
The oncologist - 1 Jul 2017
Siano Marco, Molinari Francesca, Martin Vittoria, Mach Nicolas, Früh Martin, Freguia Stefania, Corradino Irene, Ghielmini Michele, Frattini Milo, Espeli Vittoria
Abstract excerpt
LESSONS LEARNED: Panitumumab shows activity in terms of disease control rate and preventing disease progression but not for tumor shrinkage in head and neck squamous cell cancer for second-line treatment. Epidermal growth factor receptor (EGFR) copy number gain, a property of tumor cells that theoretically could identify patients more likely to experience disease response, was common among patients having disease...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.